No Data
No Data
Northeast Pharmaceutical Gets Registration Certificate for Vildagliptin Tablets
Northeast Pharmaceutical's (SHE:000597) unit, Shenyang First Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for vildagliptin tablets, th
Northeast Pharmaceutical Group (000597.SZ) has obtained the pharmaceutical registration certificate for Vigilantin tablets.
On July 8, Gelonhui reported that Northeast Pharmaceutical Group (listed as 000597.SZ) announced that recently, its wholly-owned subsidiary, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" (acceptance number: CYHS2202151, certificate number: 2024S01432) issued by the State Drug Administration for Voglibose tablets. The original research enterprise for Voglibose tablets was Novartis AG, and its domestic marketed name is "Jiawei Le". Voglibose tablets are used for the treatment of type 2 diabetes.
Northeast Pharmaceutical Group (000597.SZ) is one of the global mainstream suppliers of vitamins C.
Northeast Pharmaceutical Group (000597.SZ) stated on the investor interaction platform on July 4 that the company is one of the global mainstream suppliers of Vitamin C. The company's Vitamin C series includes effervescent tablets, solid drinks and other products, forming a diversified, specialized and serialized large health product system.
Northeast Pharmaceutical Group (000597.SZ) has received a CEP certificate for the active pharmaceutical ingredient vitamin C issued by the European Medicines Agency for quality management of pharmaceuticals.
Northeast Pharmaceutical Group (000597.SZ) announced that it has recently received a Certificate of Suitability to the European Pharmacopoeia (CEP certificate) issued by the European Medicines Quality Management Agency. Vitamin C is used for the prevention and treatment of scurvy, various acute and chronic infectious diseases or other diseases to enhance the body's resistance, as well as for the auxiliary treatment of post-illness recovery, trauma healing and allergic diseases.
Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process
Northeast Pharmaceutical (000597.SZ) plans to pay 1 yuan for every 10 shares in 2023, excluding interest on May 23
Northeast Pharmaceutical (000597.SZ) announced that in 2023, the company plans to distribute cash to all shareholders for every 10 shares...
No Data